<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939779</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-18-1-08</org_study_id>
    <nct_id>NCT04939779</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover, Phase 1 Trial to Evaluate Bioequivalence of &quot;LCB01-0371(Batch#1650006)&quot; and &quot;LCB01-0371(Batch#3183817R)&quot; in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to evaluate bioequivalence of &quot;LCB01-0371 (Batch#&#xD;
      1650006)&quot; and &quot;LCB01-0371(Batch#3183817R) in healthy adult subject&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation: The observed maximum concentration(Cmax)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Pharmacokinetic parameters will be assessed using non-compartmental method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation:Area under the blood concentration-time curve (AUClast)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Area under the plasma concentration curve from zero until the last measurable concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Time to reach Cmax(Tmax)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Pharmacokinetic parameters will be assessed using non-compartmental method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Elimination half-life(t1/2)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Pharmacokinetic parameters will be assessed using non-compartmental method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Apparent total body clearance after extravascular administration(CL/F)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Pharmacokinetic parameters will be assessed using non-compartmental method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation:Apparent volume of distribution after extravascular administration(Vd/F)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Pharmacokinetic parameters will be assessed using non-compartmental method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation:Area under the blood concentration-time curve (AUCinf)</measure>
    <time_frame>0-12hours</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinite time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A person who is a healthy adult aged between 19 and 45 years old with the result of&#xD;
             BMI between 18.0 kg/m2 and 28.0 kg/m2&#xD;
&#xD;
          2. A healthy adult whose weight is over 50 kg&#xD;
&#xD;
          3. A person who is deemed suitable for a clinical trial subject in physical examination,&#xD;
             vital sign tests, diagnostic examination, and 12-lead ECG by the medical doctor, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A person who has a clinically significant history of the disease, such as liver,&#xD;
             kidney, gastrointestinal disease, respiratory tract disease, muscular-skeletal&#xD;
             disease, endocrine disease, nervous system disease, blood âˆ™ tumor disease,&#xD;
             cardiovascular disease, etc.&#xD;
&#xD;
          2. A person who has a history of gastrointestinal diseases or surgery that may affect the&#xD;
             absorption of IP, etc.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Yong Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delpazolid</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

